Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

POUR Luděk ŠVÁCHOVÁ Hana ADAM Zdeněk ALMASI Martina KRÁLOVÁ Dana BÜCHLER Tomáš KOVÁŘOVÁ Lucie KREJČÍ Marta MICHÁLEK Jaroslav PENKA Miroslav VORLÍČEK Jiří HÁJEK Roman

Year of publication 2010
Type Article in Periodical
Magazine / Source European Journal of Haematology
MU Faculty or unit

Faculty of Medicine

Citation
Web http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2009.01396.x/pdf
Doi http://dx.doi.org/10.1111/j.1600-0609.2009.01396.x
Field Oncology and hematology
Keywords angiogenesis; chemokines; bortezomib; multiple myeloma; therapeutic response
Description Multiple myeloma (MM) is associated with increased rate of bone marrow angiogenesis. Increased concentration of hepatocyte growth factor (HGF) is associated with poor prognosis in patients treated with conventional chemotherapy or thalidomide. We have shown previously that decreased level of thrombospondin, an angiogenesis inhibitor, correlates with poor response to high-dose chemotherapy. The aim of our current study was to evaluate association between therapeutic response to bortezomib and thrombospondin and HGF levels. Peripheral blood plasma concentration of HGF and bone marrow plasma concentration of thrombospondin were measured in patients with MM prior to the initiation of bortezomib therapy. Overall, 58 patients were enrolled, 44/58 (76%) of them with relapsed disease. Treatment outcomes were analyzed for possible associations with pretreatment HGF and thrombospondin levels. Patients who achieved complete response had significantly higher pretreatment HGF levels and lower pretreatment thrombospondin levels than others. More than 70% of patients with low pretreatment HGF and high pretreatment thrombospondin concentrations achieved very good partial response or complete response, in contrast to only 20% of patients with high HGF and low thrombospondin levels. High pretreatment thrombospondin and low pretreatment HGF concentrations are associated with therapeutic response to bortezomib in patients with MM.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.